This case report details a patient with Crohn's disease (CD) who developed acute lymphoblastic leukemia (ALL) 16 years after their initial diagnosis. Various immunosuppressive therapies used in the treatment included azathioprine, infliximab and, for a short period, vedolizumab and steroids for CD and hyper-CVAD chemotherapy for leukemia. The association between CD and increased cancer risk, particularly hematological malignancies, emphasizes the importance of regular cancer surveillance, including hematological assessments, for patients on immunosuppressive therapy.